• There are no suggestions because the search field is empty.
  • Careers
  • Media
  • Investors
  • Contact us
Company
Company
Purpose
Strategy
Leadership
History
Locations
Offering
Offering
Drug Substances
Exclusive synthesis API portfolio Viral vectors
Drug Products
Oral solids Steriles Ophthalmics Inhalation products
Technologies
Sustainability
Sustainability
People
Environment
Integrity
Quality
Community engagement
Risk management
Insights

What are you
looking for?

Company
Purpose
Strategy
Leadership
History
Locations
Offering
Drug Substances
Exclusive synthesis API portfolio Viral vectors
Drug Products
Oral solids Steriles Ophthalmics Inhalation products
Technologies
Sustainability
People
Environment
Integrity
Quality
Community engagement
Risk management
Insights
  • Careers
  • Media
  • Investors
  • Contact us

Insights

Filter by tags
Technology Sustainability
NEW
11/7/2023
Technology

Tackling the key challenges in viral vector manufacturing

read article
Recent
Feb 18, 2025
Sustainability

Sustainability is part of our daily business

Jan 15, 2025
Technology

Quality Engineered: The power of QbD

Dec 15, 2024

Three success factors to accelerate your program to clinical trial

Subscribe for more expert insights

 

All posts
Mar 21, 2025

Ask better, move faster: Questions that will accelerate the speed of your program to clinical

Feb 18, 2025
Sustainability

Sustainability is part of our daily business

Jan 15, 2025
Technology

Quality Engineered: The power of QbD

Dec 15, 2024

Three success factors to accelerate your program to clinical trial

Nov 25, 2024
Technology

Insights into Evionnaz’s new R&D Center

Oct 1, 2024

De-risking complexity in pharmaceutical manufacturing

1 2 3

Sign up to stay up to date on Siegfried and our business performance.

expect more

 

Siegfried AG
Untere Brühlstrasse 4
4800 Zofingen, Switzerland

+41 62 746 11 11 info@siegfried.ch
About us
  • Our company
  • Sustainability
  • Media
  • Investors
  • Careers
Helpful resources
  • Expert insights
  • News archive
  • Reports
  • Terms and conditions
Offering
  • Drug Substances
  • Drug Products
  • Technologies

2024 © Siegfried Holding AG

Follow us on LinkedIn